Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4161-4170 Newer>

The Motley Fool September 24, 2007 Brian Lawler	An Array of Good News Small pharmaceutical firm Array BioPharma signs a big partnership deal with Celgene. Investors, take note.
The Motley Fool September 24, 2007 Brian Lawler	Seismic Shifts at PDL No matter what its hedge fund owner, Third Point, decides it wants to do with PDL, one thing is clear: A year from now, PDL BioPharma will not be the same drugmaker that it is today. Investors, take note.
The Motley Fool September 24, 2007 Brian Lawler	Encysive Hears the Voice of Reason To please the FDA, Encysive Pharmaceuticals announces it is planning an additional phase 3 trial to try and bring its lead drug, Thelin, to market in the United States.
The Motley Fool September 24, 2007 Billy Fisher	A Fountain of Youth? A study sponsored by Sirtris Pharmaceutical shows potential for the fight against aging. Investors, take note.
The Motley Fool September 24, 2007 Billy Fisher	Getting It Done at Meridian Bioscience Impressive earnings growth and disciplined spending continue to propel this small cap up and up. Investors, take note.
The Motley Fool September 24, 2007 Jack Uldrich	Nanotech Is in the Genes The FDA's stamp of approval on a genetic test that will help patients better understand how they will metabolize anti-blood clot medication gives Nanosphere extra allure. Investors should take note.
Fast Company October 1, 2007 Ellen McGirt	Business Left Undone Bill McGuire left UnitedHealth in the wake of an options scandal. While he awaits his fate, he refocuses on his great passion: reforming health care.
The Motley Fool September 21, 2007 Brian Orelli	Size Does Matter BioCryst announces failed phase 2 data with an excuse, and plans phase 3 before year-end. Investors, take note.
The Motley Fool September 21, 2007 Brian Lawler	Alexza Advances The pharmaceutical company's schizophrenia drug is ready for phase 3 testing, which will begin in the first quarter of 2008. Investors, take note.
The Motley Fool September 21, 2007 Billy Fisher	Robotics' Momentum Continues MAKO Surgical files for an IPO. The medical device maker has designed a surgeon-interactive robotic system to assist orthopedic surgeons carry out more precise and less invasive osteoarthritic knee surgeries.
<Older 4161-4170 Newer> Return to current articles.